Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation

Onkologie

Volumn 34, Issue 10, 2011, Pages 518-524

  Busemann, Christoph ^a   Wilfert, Hanna ^a   Neumann, Thomas ^a   Kiefer, Thomas ^a   Dölken, Gottfried ^a   Krüger, William H ^a,b  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Allogeneic stem cell transplantation; Conditioning therapy; Mucositis; Toxicity; Transplantrelated morbidity

Indexed keywords

BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PALIFERMIN; THYMOCYTE ANTIBODY; TREOSULFAN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RATING SCALE; REDUCED INTENSITY CONDITIONING; SIDE EFFECT; THROMBOCYTE; WHOLE BODY RADIATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LEUKOCYTE COUNT; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; MUCOSITIS; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; STATISTICS AS TOPIC; TRANSPLANTATION CONDITIONING; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 80054075118     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000332131     Document Type: Article

References (24)

1. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M: Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205. (Pubitemid 32372323)
2. Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM, Schoch HG, Fisher LD, Thomas ED: Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989;7:1288-1294. (Pubitemid 19220131)
3. Clarkson J: Palifermin improves oral mucositis after high dose chemotherapy and radiotherapy plus stem cell transplantation in people with haematological cancers. Cancer Treat Rev 2005; 31:413-416. (Pubitemid 41430695)
4. Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W: A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:1031-1035.
5. Khouri IF, Champlin RE: Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004;31:22-26. (Pubitemid 38209500)
6. Kroger N, Schetelig J, Zabelina T, Kruger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR: A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001;28:643-647. (Pubitemid 33014597)
7. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, Wegener R, Kleine HD, Wilhelm S, Knopp A, Hartung G, Dolken G, Freund M: Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004;103:725-731. (Pubitemid 38140111)
8. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, Agura E, Langston AA, Pulsipher M, Storb R, Maloney DG: Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104:3535-3542. (Pubitemid 39564424)
9. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E: Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000;96:2391-2398.
10. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M: A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GvHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;34:621-625. (Pubitemid 39341543)
11. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH: Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005;11:383-388. (Pubitemid 40542931)
12. Grosflam J, Weinblatt ME: Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity. Curr Opin Rheumatol 1991;3:363-368.
13. Montemurro M, Kiefer T, Schuler F, Al-Ali H, Wolf HH, Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Kruger W, Dolken G: Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007;18:665-671. (Pubitemid 46523269)
14. Robien K, Schubert MM, Yasui Y, Martin P, Storb R, Potter JD, Ulrich CM: Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation. Bone Marrow Transplant 2006;37:687-692.
15. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Ponisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620-1629. (Pubitemid 36182543)
16. Kroger N, Derigs G, Wandt H, Schafer-Eckart K, Wittkowsky G, Kuse R, Casper J, Kruger W, Zabelina T, Renges H, Kabisch H, Krull A, Einsele H, Zander AR: Low treatment-related mortality following allografting in advanced multiple myeloma after an intensified conditioning regimen and anti-thymocyte globulin for GvHD prevention; in Schultze W (ed): High-dose therapy and transplantation of haematopoietic stem cells (2001). Berlin, Blackwell Verlag, 2002, pp 88-96.
17. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R: Mini-allografts: ongoing trials in humans [editorial]. Bone Marrow Transplant 2000;25:345-350. (Pubitemid 30114026)
18. Kruger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G, Schuttrumpf S, Silling G, Ullmann AJ, Waldschmidt DT, Wolf HH: Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 2005;16:1381-1390. (Pubitemid 41158485)
19. Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A: Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. J Hosp Infect 2003;53: 283-291. (Pubitemid 38002040)
20. Baron F, Storb R: Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004;26:71-94. (Pubitemid 40021958)
21. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S, Miron S, Zilberman I, Slavin S, Or R: Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant 2004;34:155-159. (Pubitemid 39077107)
22. Zander AR, Berger C, Kroger N, Stockschlader M, Kruger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schonrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Witt M, Hossfeld KD, Weh HJ: High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997;3:2671-2675.
23. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905. (Pubitemid 28446849)
24. Bohme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H, Heinz W, Junghanss C, Karthaus M, Kruger W, Krug U, Kubin T, Penack O, Reichert D, Reuter S, Silling G, Sudhoff T, Ullmann AJ, Maschmeyer G: Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110.